Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

EMA’s Ben Venue Recommendations Confirm Interim Advice

Feb. 16 (Bloomberg) -- The European Medicines Agency confirmed its initial advice and gave final recommendations for 12 out of 14 centrally authorized medicines manufactured at Ben Venue Laboratories’ Ohio site.

The medicines can continue to be prescribed as before, the EMA said today in an e-mailed statement. The drugs include Angiox, Busilvex, Vidaza, Vistide, Velcade, Ecalta diluent, Soliris, Cayston, Luminity, Mepact, Torisel and Vibativ, the EMA said.

Link to Company News:{BING GR <Equity> CN <GO>} Link to Company News:{2738827Z US <Equity> CN <GO>}

To contact the editor responsible for this story: Kristen Hallam at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.